PDCD1 and melanoma: Immune checkpoint inhibitors targeting the PD-1/PD-L1 interaction have been approved as basic clinical drugs in the treatment of melanoma, non-small cell lung cancer (NSCLC), renal carcinoma, and many other malignancies [23].